Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial
Primary Purpose
Infection
Status
Recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
duration of standard antibiotic therapy
Sponsored by
About this trial
This is an interventional treatment trial for Infection
Eligibility Criteria
Inclusion Criteria:
- Spine surgery and intraoperative debridement with any technique
- At least 12 months of scheduled follow-up from hospitalization
- Bacterial spine infection of any nature, independently of implants or co-morbidities
Exclusion Criteria:
- Mycobacterial, fungal, nocardial, and Actinomyces infections in the spine
- Non-resected cancer in the infection site
- Bone marrow or recent solid organ transplant patient (Recent: <5 years)
- Any other infection in the patient requiring more than 6 weeks of antibiotic therapy
- More than three intraoperative debridements performed for spine infection
- Absence of at least one surgical intraoperative debridement of infection
Sites / Locations
- Balgrist University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
short antibiotic therapy
long antibiotic therapy
Arm Description
3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
Outcomes
Primary Outcome Measures
Remission of infection at 12 months after treatment
no clinical and microbiological recurrences
Secondary Outcome Measures
costs
total costs for treatment of infection
duration of sick leave
duration of sick leave for treatment of infection
length of hospital stay
number of days of hospital stay
Full Information
NCT ID
NCT04048304
First Posted
July 12, 2019
Last Updated
February 28, 2023
Sponsor
Balgrist University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04048304
Brief Title
Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial
Official Title
Short Post-surgical Antibiotic Therapy in Spine Infections - a Pro-spective, Randomized, Unblinded, Non-inferiority Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 31, 2019 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Balgrist University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
We implement a prospective, randomized, unblinded, non-inferiority trial regarding the duration of systemic, targeted antibiotic therapy after the first surgical debridement for spine infection; randomizing 1:1 between
Six and twelve weeks of antibiotic therapy if there is an implant left in place
Three and six weeks of antibiotic therapy if there is no implant left
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
1:1 randomization
Masking
None (Open Label)
Allocation
Randomized
Enrollment
236 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
short antibiotic therapy
Arm Type
Experimental
Arm Description
3 weeks of antibiotic therapy with no implant left in place 6 weeks of antibiotic therapy with implant left in place
Arm Title
long antibiotic therapy
Arm Type
Active Comparator
Arm Description
6 weeks of antibiotic therapy with no implant in place 12 weeks of antibiotic therapy with implant left in place
Intervention Type
Drug
Intervention Name(s)
duration of standard antibiotic therapy
Other Intervention Name(s)
Co-amoxiclav, vancomycin
Intervention Description
antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
Primary Outcome Measure Information:
Title
Remission of infection at 12 months after treatment
Description
no clinical and microbiological recurrences
Time Frame
12 months after treatment
Secondary Outcome Measure Information:
Title
costs
Description
total costs for treatment of infection
Time Frame
up to 12 months
Title
duration of sick leave
Description
duration of sick leave for treatment of infection
Time Frame
up to 12 months
Title
length of hospital stay
Description
number of days of hospital stay
Time Frame
up to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Spine surgery and intraoperative debridement with any technique
At least 12 months of scheduled follow-up from hospitalization
Bacterial spine infection of any nature, independently of implants or co-morbidities
Exclusion Criteria:
Mycobacterial, fungal, nocardial, and Actinomyces infections in the spine
Non-resected cancer in the infection site
Bone marrow or recent solid organ transplant patient (Recent: <5 years)
Any other infection in the patient requiring more than 6 weeks of antibiotic therapy
More than three intraoperative debridements performed for spine infection
Absence of at least one surgical intraoperative debridement of infection
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ilker Uckay, PD Dr med
Phone
+41 44 386 1111
Email
ilker.uckay@balgrist.ch
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Betz, PD Dr med
Phone
+41 44 386 1111
Email
michael.betz@balgrist.ch
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ilker Uckay, PD Dr med
Organizational Affiliation
Balgrist University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Balgrist University Hospital
City
Zürich
State/Province
Zurich
ZIP/Postal Code
8008
Country
Switzerland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ilker Uckay, MD
Phone
+41 44 386 37 05
Email
ilker.uckay@balgrist.ch
First Name & Middle Initial & Last Name & Degree
Regula Schupbach
Phone
+41 44 510 73 75
Email
regula.schuepbach@balgrist.ch
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
identifying IPD will not be shared with other Researchers
Citations:
PubMed Identifier
32028985
Citation
Betz M, Uckay I, Schupbach R, Grober T, Botter SM, Burkhard J, Holy D, Achermann Y, Farshad M. Short postsurgical antibiotic therapy for spinal infections: protocol of prospective, randomized, unblinded, noninferiority trials (SASI trials). Trials. 2020 Feb 6;21(1):144. doi: 10.1186/s13063-020-4047-3.
Results Reference
derived
Learn more about this trial
Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial
We'll reach out to this number within 24 hrs